The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis
- PMID: 32038120
- PMCID: PMC7003639
- DOI: 10.17179/excli2019-1842
The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis
Abstract
Hepatocellular carcinoma or Liver cancer (LC) is the sixth most common cancer and the fourth cause of death worldwide in 2018. There has not been a comprehensive study on the survival rate of patients with LC in Asia yet. Therefore, the present study was conducted to evaluate the survival rate of patients with LC in Asian countries. The methodology of the present study is based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement. The researchers searched five international databases including Medline/PubMed, Scopus, Embase, Web of Knowledge and ProQuest until July 1, 2018. We also searched Google Scholar for detecting grey literature. The Newcastle-Ottawa Quality Assessment Form was used to evaluate the quality of selected papers. A total of 1425 titles were retrieved. 63 studies met the inclusion criteria. Based on the random-effect model one-year, three-year and five-year survival rate of LC were 34.8 % (95 % CI; 30.3-39.3), 19 % (95 % CI ; 18.2-21.8) and 18.1 % (95 % CI ;16.1-20.1) respectively. According to the results of our study, the LC survival rate in Asian countries is relatively lower than in Europe and North America.
Keywords: Asia; hepatocellular carcinoma; meta-analysis; survival rate; systematic review.
Copyright © 2020 Hassanipour et al.
Figures
References
-
- Agarwal A, Yadav AK, Kumar A, Gupta S, Panwala HK, Redhu N, et al. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern india. Indian J Gastroenterol. 2015;34:117–126. - PubMed
-
- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (concord-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–1075. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous